Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography (vol 13, pg 703, 1998)

Authors
Aboagye, EO Kelson, AB Tracy, M Workman, P
Citation
Eo. Aboagye et al., Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography (vol 13, pg 703, 1998), ANTI-CAN DR, 13(8), 1998, pp. 1009-1010
Citations number
1
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTI-CANCER DRUG DESIGN
ISSN journal
02669536 → ACNP
Volume
13
Issue
8
Year of publication
1998
Pages
1009 - 1010
Database
ISI
SICI code
0266-9536(199812)13:8<1009:PDACSO>2.0.ZU;2-H